Third, given accumulating evidence of ketoacidosis, nutritional deficiency, and other serious adverse events with GLP-1 RAs, clinicians should provide clear counseling on safe use, screen for red-flag symptoms, monitor nutritional status, and maintain a low threshold for hospital assessment in patients using these agents for weight loss outside structured diabetes care pathways. This evidence concerns the gene GLP1R and diabetes mellitus.